With respect to the primary efficacy outcomes, GLP‐1 or GIP/GLP‐1 RA treatment was associated with a significantly lower risk of papilledema (RR: 0.25; 95% CI: 0.15 to 0.43; p < 0.01; 2 studies; I2 = 44%; p for Cochran's Q = 0.18; Figure 1a) and visual disturbances or blindness (RR: 0.41; 95% CI: 0.18 to 0.92; p = 0.03; 2 studies; I2 = 81%; p for Cochran's Q = 0.02; Figure 1b) compared with standard of care. This evidence concerns the gene GCG and Blindness.